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Figure 1. The Mitochondrial Carnitine System. Linus Palding Institute at 
Oregon State University. http://lpi.oregonstate.edu/infocenter/othernuts/














































  –  Usually	noted	during	first	or	second	decade	of	life,	but	can	appear	as	late	as	the	fifth	decade.	
  –  Characterized	by	attacks	of	myalgia,	muscle	stiffness	or	tenderness,	weakness,	and	fatigue,	with	or	without	myoglobinuria.	Lethargy	and	seizures	can	happen.		
  –  When	rhabdomyolysis	occurs,	it	may	lead	to	acute	renal	failure,	electrolytes	abnormality	causing	cardiac	arrhythmias,	and	respiratory	insufficiency	requiring	mechanical	
ventilation.
•	 	Triggers:	
  –  Prolonged	exercise
  –  Cold	exposure
  –  Fever
  –  Stress	or	infection
  –  Medications	that	may	lower	carnitine	levels,	like	pentobarbital,	phenytoin,	carbamazepine,	depakote,	sulfadiazine,	pyrimethamine,	
cefditoren,	ipecac,	and	zidovudine.	
•	 	Diagnosis	
  –  Determination	of	free	and	acylcarnitine	levels	in	serum,	urine	and/tissues.
  –  Confirmation	by	direct	enzymatic	assay	or	DNA	analysis.	
•	 	Treatments;	no	specific	treatment	exists.	Preventive	measures	include;
  –  Diet	modification;	high	carbohydrate,	low	(medium-chain)	fat	and	low	protien	diet.	Frequent	meals.	Extra	carbohydrate	intake	before	sustained	exercise	appears	to	improve	
exercise	intolerance.
  –  Triheptanoin	diet	appears	promising.	Larger	studies	are	needed	to	confirm.
  –  Refrain	from	prolonged	aerobic	exercise,	fasting	and	cold	exposure.
  –  Pharmacologic	treatment	with	bezafibrate	may	be	beneficial	for	mild	CPT	II	deficiency.	Larger	studies	are	needed	to	confirm.	
Figure 2. CPT II Deficiency.The carnitine cycle in fatty acid oxidation. 
In: Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine 
transport and the carnitine cycle. American Journal Of Medical Genetics. 
Part C, Seminars In Medical Genetics. May 15, 2006;142C(2):77-85.
Carnitine Palmitoyltransferase II Deficiency:
•	 	It	has	an	autosomal	recessive	pattern	of	inheritance.	
•	 	A	majority	of	affected	individuals	are	homozygous	or	compound	heterozygotes	for	mutations	in	the	CPT	
II	gene.
•	 	The	two	most	common	gene	defects,	S113L	and	R503C	may	cause	disease	in	heterozygotes.
•	 	The	three	clinical	presentations	are:	lethal	neonatal	form,	severe	infantile	hepatocardiomuscular	form,	
and	myopathic	form.	The	former	2	presentations	are	fatal	at	young	age.
Teaching Point:
•	 	Internists	need	to	be	aware	of	the	manifestations	of	inborn	error	of	muscle	metabolism	which	can	also	present	in	adults.	This	case	was	diagnosed	14	years	after	her	
initial	presentation	and	after	been	evaluated	by	22	specialists.	
